[go: up one dir, main page]

WO2000066590A3 - Tetracyclic progesterone receptor modulator compounds and methods - Google Patents

Tetracyclic progesterone receptor modulator compounds and methods Download PDF

Info

Publication number
WO2000066590A3
WO2000066590A3 PCT/US2000/011750 US0011750W WO0066590A3 WO 2000066590 A3 WO2000066590 A3 WO 2000066590A3 US 0011750 W US0011750 W US 0011750W WO 0066590 A3 WO0066590 A3 WO 0066590A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
progesterone receptor
methods
receptor modulator
tetracyclic
Prior art date
Application number
PCT/US2000/011750
Other languages
French (fr)
Other versions
WO2000066590A2 (en
Inventor
Lin Zhi
Todd K Jones
Keith B Marschke
Christopher M Tegley
Andrew Fensome
Puwen Zhang
Jay E Wrobel
James P Edwards
Original Assignee
Ligand Pharm Inc
American Home Prod
Lin Zhi
Todd K Jones
Keith B Marschke
Christopher M Tegley
Andrew Fensome
Puwen Zhang
Jay E Wrobel
James P Edwards
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/552,353 external-priority patent/US6358947B1/en
Application filed by Ligand Pharm Inc, American Home Prod, Lin Zhi, Todd K Jones, Keith B Marschke, Christopher M Tegley, Andrew Fensome, Puwen Zhang, Jay E Wrobel, James P Edwards filed Critical Ligand Pharm Inc
Priority to AU45018/00A priority Critical patent/AU4501800A/en
Priority to EP00926495A priority patent/EP1175422A2/en
Priority to MXPA01011294A priority patent/MXPA01011294A/en
Priority to CA002371273A priority patent/CA2371273A1/en
Priority to HK02104861.6A priority patent/HK1043788A1/en
Priority to JP2000615620A priority patent/JP2002543204A/en
Publication of WO2000066590A2 publication Critical patent/WO2000066590A2/en
Publication of WO2000066590A3 publication Critical patent/WO2000066590A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Nonsteroidal compounds that are high affinity, high selectivity modulators for progesterone receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring progesterone receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the progesterone receptor modulator compounds.
PCT/US2000/011750 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods WO2000066590A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU45018/00A AU4501800A (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods
EP00926495A EP1175422A2 (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods
MXPA01011294A MXPA01011294A (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods.
CA002371273A CA2371273A1 (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods
HK02104861.6A HK1043788A1 (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods
JP2000615620A JP2002543204A (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulatory compounds and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30461499A 1999-05-04 1999-05-04
US60/183,044 1999-05-04
US09/552,353 2000-04-19
US09/552,353 US6358947B1 (en) 1999-05-04 2000-04-19 Tetracyclic progesterone receptor modulator compounds and methods

Publications (2)

Publication Number Publication Date
WO2000066590A2 WO2000066590A2 (en) 2000-11-09
WO2000066590A3 true WO2000066590A3 (en) 2001-02-08

Family

ID=26974128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011750 WO2000066590A2 (en) 1999-05-04 2000-05-01 Tetracyclic progesterone receptor modulator compounds and methods

Country Status (6)

Country Link
EP (1) EP1175422A2 (en)
CN (1) CN1353717A (en)
AU (1) AU4501800A (en)
CA (1) CA2371273A1 (en)
HK (1) HK1043788A1 (en)
WO (1) WO2000066590A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535029A (en) * 1999-08-31 2003-11-25 イエナファルム ゲゼルシャフト ミット ベシュレンクテル ハフツング Mesoprogestin (progesterone receptor modulator) for the treatment and prevention of benign hormone-dependent gynecological diseases
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
KR20020038745A (en) * 1999-08-31 2002-05-23 타우버트 디터, 레흐만 흘거,디테르 타우베르트 홀게르 레만 Mesoprogestins (Progesterone Receptor Modulators) as a Component of Female Contraceptives
MXPA05003800A (en) 2002-10-11 2005-06-08 Ligand Pharm Inc 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h.
TW200410968A (en) 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5281291B2 (en) 2005-01-10 2013-09-04 グラクソ グループ リミテッド New compounds
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
DE102005030294A1 (en) * 2005-06-24 2007-01-04 Schering Ag Nonsteroidal progesterone receptor modulators
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20071068A1 (en) 2005-12-20 2007-12-13 Glaxo Group Ltd 3- (4 - {[4- (4 - {[3- (3,3-DIMETHYL-1-PIPERIDINYL) PROPYL] OXY} PHENYL) -1-PIPERIDINYL] CARBONYL} -1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID, SALTS OF THE SAME, AS ANTAGONISTS OF THE H1 AND H3 RECEPTORS
EA200801997A1 (en) 2006-04-20 2009-04-28 Глаксо Груп Лимитед NEW CONNECTIONS
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
ATE552255T1 (en) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-AMINOINDAZOLES
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2010107955A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
JP2012520685A (en) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521762A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of nerve growth factor β chain (NGFβ) gene expression using small interfering nucleic acids (siNA)
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
AR076373A1 (en) 2009-04-24 2011-06-08 Glaxo Group Ltd N-PIRAZOLIL CARBOXAMIDS AS CALCIUM CHANNEL INHIBITORS
TWI562992B (en) 2009-04-30 2016-12-21 Glaxo Group Ltd Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
JP2013512879A (en) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Benzpyrazole derivatives as inhibitors of PI3 kinase
JP2013512878A (en) 2009-12-03 2013-04-18 グラクソ グループ リミテッド New compounds
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
PT2614058E (en) 2010-09-08 2015-10-27 Glaxosmithkline Ip Dev Ltd Polymorphs and salts of n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-& xa;1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide
ES2602972T3 (en) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US9156791B2 (en) 2010-10-21 2015-10-13 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
KR20160062178A (en) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Pi3k inhibitor for treatment of respiratory disease
EP3057587A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
US9394281B2 (en) 2014-03-28 2016-07-19 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CR20160529A (en) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd PHARMACEUTICAL COMPOSITIONS TO TREAT INFECTIOUS DISEASES
JP2018527362A (en) 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Substituted heteroaryl compounds and methods of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
JP2022529341A (en) 2019-04-19 2022-06-21 リガンド・ファーマシューティカルズ・インコーポレイテッド The crystalline form of the compound and the method for producing the crystalline form of the compound.
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5688808A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5688808A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5693647A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods

Also Published As

Publication number Publication date
HK1043788A1 (en) 2002-09-27
WO2000066590A2 (en) 2000-11-09
EP1175422A2 (en) 2002-01-30
AU4501800A (en) 2000-11-17
CA2371273A1 (en) 2000-11-09
CN1353717A (en) 2002-06-12

Similar Documents

Publication Publication Date Title
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
AU4597796A (en) Steroid receptor modulator compounds and methods
MX9704640A (en) Steroid receptor modulator compounds and methods.
AU3508497A (en) Androgen receptor modulator compounds and methods
AU7109000A (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes
WO2000006085A3 (en) Compounds and methods
EP1425277B8 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
WO2004089942A3 (en) Benzimidazolidinone derivatives as muscarinic agents
WO2002008221A3 (en) Capsaicin receptor ligands
WO2003028650A3 (en) Benzimidazolidinone derivatives as muscarinic agents
WO1998058911A3 (en) Prostaglandin agonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
HUP0104588A3 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators pharmaceutical compositions comprising thereof, method for their preparation and their use
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs
CA2259031A1 (en) Androgen receptor modulator compounds and methods
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
SI1200402T1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HK1066736A (en) Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808438.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 615620

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2371273

Country of ref document: CA

Ref document number: 2371273

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011294

Country of ref document: MX

Ref document number: 2000926495

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 45018/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000926495

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2000926495

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000926495

Country of ref document: EP